Anesthesia for Electroconvulsive Therapy


Electroconvulsive Therapy (ECT) is a therapeutic procedure primarily used for patients with pharmacotherapy-resistant psychiatric disorders, most notably depression. This treatment modality, introduced in the 1930s, involves inducing a controlled seizure through electrical stimulation of the brain while the patient is under general anesthesia. ECT aims to provide hemodynamic stability, induce amnesia, and achieve muscle relaxation to ensure effective patient treatment.

Anatomy and Physiology:
During ECT, a seizure is purposefully triggered using an external electrical device while the patient is in a state of general anesthesia. This induced seizure results in a generalized tonic-clonic seizure, the duration of which can vary from patient to patient.
Seizures during ECT provoke profound autonomic nervous system activity. Initially, the parasympathetic nervous system is activated, which can lead to bradycardia and, in some cases, asystole (a lack of cardiac electrical activity). This bradycardia is typically short-lived, followed by a surge in sympathetic nervous system activity. This surge results in hypertension (high blood pressure) and tachycardia (elevated heart rate). The sympathetic stimulation can persist for 5 to 10 minutes after the seizure has been induced.
The parasympathetic surge, which precedes the sympathetic response, increases the risk of myocardial ischemia if severe bradycardia persists for too long. To counteract this, an anticholinergic medication like glycopyrrolate may be administered. However, anticholinergic medications can cause tachycardia, which is exacerbated during the subsequent sympathetic response.
During the sympathetic discharge phase, prolonged tachycardia and hypertension elevate the risk of cardiovascular events due to increased myocardial demand and oxygen consumption. Additionally, both sympathetic stimulation and the seizure itself cause an increase in cerebral blood flow and an elevated cerebral metabolic rate of oxygen, resulting in increased intracranial pressure. Increases in intraocular and intragastric pressure may also occur. Esmolol, a medication, can be used to mitigate the sympathetic response.
Patients may experience postictal states following the seizure, with stroke-like symptoms or cognitive agitation. This can sometimes complicate the clinical picture as patients are also recovering from the effects of general anesthesia.

Anesthesia Considerations:
Anesthesia for ECT plays a critical role in ensuring patient safety and the success of the procedure. General anesthesia is essential to prevent awareness and discomfort during the induced seizure. Key anesthesia considerations include:

  • Anesthetic Agents: Anesthetic agents like methohexital, etomidate, propofol, ketamine, and sevoflurane are used to induce and maintain anesthesia during ECT. The choice of agent depends on factors like seizure duration and patient characteristics.
  • Muscle Relaxants: Succinylcholine or non-depolarizing neuromuscular blockers like rocuronium are used to achieve muscle relaxation, preventing musculoskeletal injuries during the seizure.
  • Monitoring: Continuous monitoring of heart rate, oxygen saturation, blood pressure, and EEG is essential to ensure the patient’s safety and the effectiveness of the procedure.
  • Hyperventilation: Inducing hypocapnia through hyperventilation helps lower cerebral blood flow and reduce the seizure threshold.
  • Anticholinergic Medications: Glycopyrrolate may be administered to counteract parasympathetic effects and reduce the risk of bradycardia.
  • Recovery: Patients are monitored closely in a post-anesthesia unit to ensure they are stable before discharge or transfer to a hospital room.
  1. Severe Depression: ECT is a first-line treatment for severe depression, especially when accompanied by psychotic features or a high risk of suicide.
  2. Catatonia: Patients with catatonic symptoms or psychomotor retardation, such as the inability to eat or drink, benefit from ECT, as it can provide rapid relief.
  3. Neuroleptic Malignant Syndrome: ECT is indicated in cases of neuroleptic malignant syndrome, a life-threatening condition.
  4. Pregnancy: When medication poses risks to the patient or fetus, ECT may be used to treat severe depression with psychotic features during pregnancy.
  5. Treatment-Resistant Conditions: ECT is a second-line treatment when pharmacotherapy is ineffective or symptoms worsen.
  6. Experimental Uses: ECT is considered for experimental treatments in conditions like treatment-resistant epilepsy, Parkinson’s disease, depression with tremors, and Tourette syndrome.
  • Absolute Contraindications: ECT is absolutely contraindicated in cases of pheochromocytoma due to the risk of extreme hemodynamic instability. Elevated intracranial pressure with mass effect at baseline is also an absolute contraindication because of the potential exacerbation during ECT.
  • Relative Contraindications: Patients with intracranial masses, retinal detachment, or intracerebral aneurysms may not tolerate the increase in intracranial or intraocular pressure induced by ECT. Additionally, patients with underlying myocardial disease, cardiac arrhythmias, bleeding disorders, or pheochromocytoma should be carefully assessed for their ability to tolerate the hemodynamic fluctuations during the procedure.
  • Common complications of Electroconvulsive Therapy (ECT) include temporary headaches and cognitive impairment, often exacerbated by general anesthesia and underlying psychiatric conditions.
  • Prolonged seizures during ECT can lead to status epilepticus, a condition requiring prompt treatment with benzodiazepines or propofol until seizure termination.
  • Induction of general anesthesia and muscle relaxation may make mask ventilation difficult, potentially necessitating endotracheal intubation to prevent severe hypoxia.
  • Post-ECT recovery in the post-anesthesia care unit may be associated with risks such as myocardial infarction, ischemic or hemorrhagic stroke, agitation, and pain.
  • Postictal side effects, including paralysis or mania, can also occur.
Special Considerations:
  • Patients with deep brain stimulators should have them turned off during ECT to prevent electrical interference, and consultation with a specialized physician may be necessary.
  • Patients with cardiac devices (pacemakers) are generally safe to undergo ECT with ECG monitoring, but a magnet should be available in case of emergencies, and communication with the cardiologist is essential.
  • ECT is highly effective for pharmacotherapy-resistant depression and other severe psychiatric disorders, with quick results often requiring multiple sessions.
  • General anesthesia for ECT ensures a safe environment for inducing a controlled epileptic seizure, treating hemodynamic instability, and preventing painful and harmful side effects.
  • The choice of anesthetic agents aims to provide amnesia with minimal impact on hemodynamics and seizure duration, allowing customization to individual patient needs.
  • Anesthesia is crucial for patient safety during ECT, as it minimizes harm and trauma, particularly compared to ECT without anesthesia, which can lead to musculoskeletal injury and post-traumatic stress disorder.

Leave a Comment